Company profile: Aptevo Therapeutics
1.1 - Company Overview
Company description
- Provider of bispecific immunotherapies and platform technologies for cancer treatment, focused on oncology and hematology. Portfolio includes ADAPTIR and ADAPTIR-FLEX platforms, plus candidates APVO436 (CD3xCD123, Phase 2 AML), APVO603 (4-1BB/OX40), APVO442 (PSMA/CD3 for prostate cancer), and APVO711 (PD-L1/CD40).
Products and services
- ADAPTIR Platform: Proprietary technology platform engineers bispecific immunotherapies with multiple mechanisms of action for cancer treatment
- ADAPTIR-FLEX Platform: Heterodimer platform technology produces bispecific and multi-specific antibody candidates for targeting multiple cancer antigens
- APVO436: Clinical-stage bispecific CD3xCD123 ADAPTIR molecule redirects the immune system to destroy leukemia cells expressing CD123, in Phase 2 trials for treating Acute Myeloid Leukemia (AML)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aptevo Therapeutics
Juno Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies for the treatment of cancer, formed through a unique partnership with Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute to advance a broad pipeline of breakthrough immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Juno Therapeutics company profile →
IDEC Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapy development targeting neurodegenerative, hematologic, and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IDEC Pharmaceuticals company profile →
Dice Therapeutics
HQ: United States
Website
- Description: Provider of oral small-molecule therapeutics for chronic autoimmune, inflammatory, and other diseases, leveraging a proprietary platform to build a pipeline targeting well-validated immunology pathways. Programs include IL-17 inhibitors (DC-806, DC-853) and novel scaffolds, oral α4β7 for IBD, oral αVβ1/αVβ6 for fibrotic diseases including idiopathic pulmonary fibrosis, and oral PD-L1 inhibitors for cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dice Therapeutics company profile →
Ultivue
HQ: United States
Website
- Description: Provider of tissue imaging and multiplex biomarker assay solutions for precision medicine research, including InSituPlex DNA-barcoded antibody technology, custom assay development, pre-optimized ready-to-use multiplex staining kits, specialized AI tools and full lifecycle image analysis for multiplex immunofluorescence, and OmniVUE customizable biomarker panel design kits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultivue company profile →
SpringWorks Therapeutics
HQ: United States
Website
- Description: Provider of targeted oncology therapies for cancer and rare diseases, focused on innovative treatments for unmet needs. Portfolio includes nirogacestat, an oral gamma secretase inhibitor for desmoid tumors and in evaluation for ovarian granulosa cell tumors and multiple myeloma; mirdametinib, a MEK inhibitor for NF1-associated plexiform neurofibromas; brimarafenib (BGB-3245), a RAF fusion/dimer inhibitor; and SW-682, a TEAD inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SpringWorks Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aptevo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aptevo Therapeutics
2.2 - Growth funds investing in similar companies to Aptevo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aptevo Therapeutics
4.2 - Public trading comparable groups for Aptevo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →